Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
N/A
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01211028Phase 1Completed

Adipose CELL Derived Regenerative Endothelial Angiogenic Medicine

Role: collaborator

NCT01274455Phase 1Completed

Gene Therapy of Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT01146548Phase 2Completed

Fluoxetine in Multiple System Atrophy Patients

Role: collaborator

NCT00908557Not ApplicableCompleted

Impact of Readability Improvements on the Comprehension of Written Information Given to Clinical Trial Patients: a RCT

Role: collaborator

All 4 trials loaded